What is the Outlook for Crispr Therapeutics AG (CRSP) Stock?

Thursday, April 23, 2020 1:45 PM | InvestorsObserver Analysts

Crispr Therapeutics AG (CRSP) stock has risen 38.14% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 62 out of a possible 100.

That rank is mainly influenced by a short-term technical score of 79. CRSP's rank also includes a long-term technical score of 76. The fundamental score for CRSP is 31. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 71.222. This means analysts expect the stock to increase 33.67% over the next 12 months.

Overall Score - 62
CRSP has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on CRSP!

What's Happening with CRSP Stock Today

Crispr Therapeutics AG (CRSP) stock has risen 1.68% while the S&P 500 has risen 0.41% as of 1:42 PM on Thursday, Apr 23. CRSP has risen $0.88 from the previous closing price of $52.40 on volume of 260,964 shares. Over the past year the S&P 500 is down -3.98% while CRSP has risen 38.14%. CRSP earned $1.17 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 45.37.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Share this article:

Related Companies

You May Also Like

Related Articles

BMO's Markets Wrap

European Bourses Track Higher Midday, Tech Sector Strong

Wall Street Leans Forward Pre-Bell; Futures Green, Europe Up, Asia Higher

Asian Stock Markets Higher on US Stimulus Outlook, Tech Strength

Related Companies